# A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

> **NCT07464925** · PHASE1 · RECRUITING · sponsor: **Tetragon Biosciences Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma Multiforme of Brain
- Glioma
- Glioblastoma

## Interventions

- **DRUG:** GLIX1

## Key facts

- **NCT ID:** NCT07464925
- **Lead sponsor:** Tetragon Biosciences Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07464925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07464925, "A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07464925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*